8-K: NKGen Biotech Secures $2.5 Million Investment via Stock and Warrant Purchase Agreement

NKGen Biotech entered into a stock purchase agreement with CFIC-2015 NV Family Investments, LLC, for an aggregate purchase price of $2.5 million, involving the issuance of common stock and warrants.

Summary

• NKGen Biotech, Inc. has entered into a Stock Purchase Agreement with CFIC-2015 NV Family Investments, LLC on May 14, 2025.
• Under the agreement, NKGen Biotech will issue and sell 19,669,552 shares of its common stock at $0.1271 per share, totaling $2,500,000.
• The Share Price was determined based on the per share purchase price under the Company's most recent stock purchase agreement with Paul Y. Song, as disclosed in the Company's Current Report on Form 8-K filed on May 8, 2025.
• In addition to the shares, NKGen Biotech will issue a warrant to the purchaser, allowing them to buy up to 39,339,103 shares of common stock at the same exercise price of $0.1271.
• The offering and sale of these securities are exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.
• The purchaser has represented that it is an accredited investor as defined in Rule 501(a) under the Securities Act.
• The purchaser's payment of the Purchase Price is pending and, upon receipt of payment of the Purchase Price, the Company will issue the Shares to the Purchaser.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company is securing funding, which is generally positive. However, there is potential dilution for existing shareholders, which tempers the positive outlook.

Positives

• NKGen Biotech secures $2.5 million in funding.
• The company issues shares and warrants, potentially increasing its capital base.
• The transaction relies on exemptions from registration, simplifying the process.
• The investor is an accredited investor, indicating a level of sophistication and financial capacity.

Negatives

• The company is selling shares at $0.1271, which may be dilutive to existing shareholders.
• The warrants issued could further dilute the stock if exercised.
• The purchaser's payment of the Purchase Price is pending and, upon receipt of payment of the Purchase Price, the Company will issue the Shares to the Purchaser.

Risks

• The purchaser's payment of the Purchase Price is pending and, upon receipt of payment of the Purchase Price, the Company will issue the Shares to the Purchaser.
• The securities have not been registered and may not be offered or sold absent registration or an applicable exemption.
• Future issuances of common stock or convertible securities could trigger anti-dilution adjustments to the warrant's exercise price.
• The company's reliance on exemptions from registration may limit the pool of potential investors in the future.

Future Outlook

The company intends to use the net proceeds from the sale of the Securities hereunder for working capital and general corporate purposes.

Management Comments

• Paul Y. Song signed the report as Chief Executive Officer (Principal Executive Officer).

Industry Context

Private placements are a common method for biotech companies to raise capital, especially for those that may not yet be generating significant revenue or are pre-profitability. This allows them to fund ongoing research, clinical trials, and general operations.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as those listed on the OTC markets or smaller NASDAQ listings, often utilize similar financing methods.
• The terms of the agreement, including the share price and warrant coverage, would need to be compared to recent transactions by peer companies to assess whether they are favorable or unfavorable to NKGen Biotech.
• Companies like Mustang Bio and Celularity have used similar private placement structures to raise capital for clinical development programs.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's ability to fund its operations and research may be enhanced by the $2.5 million capital injection.
• The transaction could potentially impact the company's stock price, depending on market reaction.

Next Steps

• The purchaser needs to remit the $2.5 million payment to NKGen Biotech.
• Upon receipt of payment, NKGen Biotech will issue the 19,669,552 shares and the warrant to purchase 39,339,103 shares to CFIC-2015 NV Family Investments, LLC.
• NKGen Biotech will file a Current Report on Form 8-K with the Commission describing the terms of the Transaction Documents, and including as exhibits to such Current Report on Form 8-K the material Transaction Documents.

Key Dates

Keywords

stock purchase agreement, warrant, common stock, CFIC-2015 NV Family Investments, NKGen Biotech, capital raise, private placement, securities